Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials: 2015 ADAA Scientific Research Symposium: KORs in Psychiatric Illness
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Kappa-opioid receptor (KOR) antagonists are currently being considered for the treatment of a variety of neuropsychiatric conditions, including depressive, anxiety, and substance abuse disorders. A general ability to mitigate the effects of stress, which can trigger or exacerbate these conditions, may explain their putative efficacy across such a broad array of conditions. The discovery of their potentially therapeutic effects evolved from preclinical research designed to characterize the molecular mechanisms by which experience causes neuroadaptations in the nucleus accumbens (NAc), a key element of brain reward circuitry. This research established that exposure to drugs of abuse or stress increases the activity of the transcription factor CREB (cAMP response element binding protein) in the NAc, which leads to elevated expression of the opioid peptide dynorphin that in turn causes core signs of depressive- and anxiety-related disorders. Disruption of KORs-the endogenous receptors for dynorphin-produces antidepressant- and anxiolytic-like actions in screening procedures that identify standard drugs of these classes, and reduces stress effects in tests used to study addiction and stress-related disorders. Although interest in this target is high, prototypical KOR antagonists have extraordinarily persistent pharmacodynamic effects that complicate clinical trials. The development of shorter acting KOR antagonists together with more rapid designs for clinical trials may soon provide insight on whether these drugs are efficacious as would be predicted by preclinical work. If successful, KOR antagonists would represent a unique example in psychiatry where the therapeutic mechanism of a drug class is understood before it is shown to be efficacious in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Di Chiara, G., & Imperato, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5274 · Cited by 4,733
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“It seeks to do so by (1) identifying promising new targets in the brain that could be the basis for development of new drugs, and (2) employing methodology for rapidly assessing the promise of those targets.[100, 101] KOR antagonism was identified as among the most promising new targets and CERC-501 is being evaluated…”
The mesolimbic dopamine reward circuit in depression
Nestler, E. J., & Carlezon, W. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.018 · Cited by 2,059 · cited 2×
“The NAc is an element of the mesolimbic system, which plays a role in motivation and the pathophysiology of psychiatric illness.[1] Although elevated CREB activity leads to alterations in the function of scores of target genes,[2] it has been established that CREB-mediated increases in the expression of the endogenous…”
Self-citationWise, R. A., & Rompre, P.-P. (1989) · Annual Review of Psychology · doi:10.1146/annurev.ps.40.020189.001203 · Cited by 1,968
Psychotomimesis Mediated by κ Opiate Receptors
Pfeiffer, A., Brantl, V., Herz, A., & Emrich, H. M. (1986) · Science · doi:10.1126/science.3016896 · Cited by 857
Regulation of cocaine reward by CREB
Carlezon, W. A., Thome, J., Olson, V. G., Lane-Ladd, S. B., Brodkin, E. S., Hiroi, N., Duman, R. S., Neve, R. L., & Nestler, E. J. (1998) · Science · doi:10.1126/science.282.5397.2272 · Cited by 767
Self-citationDrug-activation of brain reward pathways
Wise, R. A. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00063-5 · Cited by 684 · cited 1×
“[51] Current evidence suggests that this is not the case: there is nothing in the literature to indicate that KOR antagonists are self-administered, and on their own they do not affect ICSS thresholds,[52] which are decreased by drugs with abuse liability.[53, 54] These findings are consistent with previous data indic…”
Expression of the transcription factor ΔFosB in the brain controls sensitivity to cocaine
Kelz, M. B., Chen, J., Carlezon, W. A., Whisler, K., Gilden, L., Beckmann, A. M., Steffen, C., Zhang, Y.-J., Marotti, L., Self, D. W., et al. (1999) · Nature · doi:10.1038/45790 · Cited by 641
Self-citationBiological substrates of reward and aversion: A nucleus accumbens activity hypothesis
Carlezon, W. A., & Thomas, M. J. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.075 · Cited by 561
Self-citationThe dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors
Bruchas, M. R., Land, B. B., & Chavkin, C. (2010) · Brain Research · doi:10.1016/j.brainres.2009.08.062 · Cited by 544
Pliakas, A. M., Carlson, R. R., Neve, R. L., Konradi, C., Nestler, E. J., & Carlezon, W. A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-18-07397.2001 · Cited by 509 · cited 5×
“[20] And fourth, the prototypical KOR antagonist norBNI blocked the prodepressive-like effects of elevated CREB function, but perhaps more importantly, produced antidepressant-like effects of its own, thereby mimicking the effects of CREB disruption.[15] This general finding has been widely replicated[21–23] and stron…”
InfluentialSelf-citationAntidepressant-Like Effects of κ-Opioid Receptor Antagonists in the Forced Swim Test in Rats
Mague, S. D., Pliakas, A. M., Todtenkopf, M. S., Tomasiewicz, H. C., Zhang, Y., Stevens, W. C., Jones, R. M., Portoghese, P. S., & Carlezon, W. A. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.046433 · Cited by 485
Self-citationPharmacological evidence for a motivational role of κ-opioid systems in ethanol dependence
Walker, B. M., & Koob, G. F. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301438 · Cited by 392
Buprenorphine Treatment of Refractory Depression
Bodkin, J. A., Zornberg, G. L., Lukas, S. E., & Cole, J. O. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502000-00008 · Cited by 346
Newton, S. S., Thome, J., Wallace, T. L., Shirayama, Y., Schlesinger, L., Sakai, N., Chen, J., Neve, R., Nestler, E. J., & Duman, R. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-24-10883.2002 · Cited by 313
Yovell, Y., Bar, G., Mashiah, M., Baruch, Y., Briskman, I., Asherov, J., Lotan, A., Rigbi, A., & Panksepp, J. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040535 · Cited by 311
Effects of κ-opioid receptor ligands on intracranial self-stimulation in rats
Todtenkopf, M. S., Marcus, J. F., Portoghese, P. S., & Carlezon, W. A. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1680-y · Cited by 273 · cited 1×
“[51] Current evidence suggests that this is not the case: there is nothing in the literature to indicate that KOR antagonists are self-administered, and on their own they do not affect ICSS thresholds,[52] which are decreased by drugs with abuse liability.”
Self-citationEnadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans
Walsh, S., Strain, E., Abreu, M., & Bigelow, G. (2001) · Psychopharmacology · doi:10.1007/s002130100788 · Cited by 258 · cited 1×
“First, administration of KOR agonists to people produces dysphoric and depressive effects.[17, 18] Second, microinjections of KOR agonists into the NAc produce conditioned place aversions resembling those seen with intermediate doses of cocaine in rats overexpressing CREB in the NAc.”
kappa-Opioid receptor signaling and brain reward function
Bruijnzeel, A. W. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.09.008 · Cited by 214
Evaluation of Opioid Modulation in Major Depressive Disorder
Ehrich, E., Turncliff, R., Du, Y., Leigh-Pemberton, R., Fernandez, E., Jones, R., & Fava, M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.330 · Cited by 169 · cited 4×
“The doses of samidorphan that led to clinically significant opioid antagonism were then administered along with a fixed dose of buprenorphine in a double-blind, placebocontrolled, cross-over trial in 32 patients with treatmentresistant depression.[99] A rapid antidepressant response was noted (observed after 7 days of…”
InfluentialPossible antidepressive effects of opioids: Action of buprenorphine
Emrich, H. M., Vogt, P., & Herz, A. (1982) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1982.tb39483.x · Cited by 152
Depressive symptoms during buprenorphine treatment of opioid abusers
Kosten, T. R., Morgan, C., & Kosten, T. A. (1990) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(90)90035-o · Cited by 110
Naltrexone and buprenorphine combination in the treatment of opioid dependence
Gerra, G., Fantoma, A., & Zaimovic, A. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106060835 · Cited by 106 · cited 1×
“[96] Evidence for a therapeutic effect was found in openlabel studies including 15 and 60 heroin-dependent individuals.[97, 98] These studies provide preliminary evidence that therapeutic effects of buprenorphine on opioid dependence may be due, at least in part, to KOR antagonism.”
Opiate Treatment in Depression Refractory to Antidepressants and Electroconvulsive Therapy
Nyhuis, P. W., Gastpar, M., & Scherbaum, N. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818638a4 · Cited by 90 · cited 1×
“This includes reports of improvement in depression in depressed opiate-dependent individuals treated with buprenorphine,[88] antidepressant effects in a doubleblind, placebo-controlled, cross-over study involving 10 depressed patients,[78] and improvement in depression in open label-studies including 10 patients with…”
Khroyan, T. V., Wu, J., Polgar, W. E., Cami‐Kobeci, G., Fotaki, N., Husbands, S. M., & Toll, L. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12796 · Cited by 40
Cited by
Opioid receptors: drivers to addiction?
Darcq, E., & Kieffer, B. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0028-x · Cited by 352
Krystal, A. D., Pizzagalli, D. A., Smoski, M., Mathew, S. J., Nurnberger, J., Lisanby, S. H., Iosifescu, D., Murrough, J. W., Yang, H., Weiner, R. D., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0806-7 · Cited by 227
Self-citationDepression Effects on Long-term Prescription Opioid Use, Abuse, and Addiction
Sullivan, M. D. (2018) · The Clinical Journal of Pain · doi:10.1097/ajp.0000000000000603 · Cited by 196
Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism
Williams, N. R., Heifets, B. D., Bentzley, B. S., Blasey, C., Sudheimer, K. D., Hawkins, J., Lyons, D. M., & Schatzberg, A. F. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0503-4 · Cited by 174
Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents
Klein, M. E., Chandra, J., Sheriff, S., & Malinow, R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916570117 · Cited by 156
Metadata
- Authors
- Carlezon, W. A., & Krystal, A. D.
- Venue
- Depression and Anxiety
- Publisher
- Wiley
- Published
- 2016-10
- Volume
- 33
- Issue
- 10
- Pages
- 895-906
- ISSN
- 1091-4269 (ISSN-L)
- OpenAlex
- W2528265397
- Cited by
- 158
- References
- 25
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.